STOCK TITAN

NewcelX (NCEL) CFO Hagai Omri reports 11,396-share option holding on Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

NewcelX Ltd. filed an initial insider ownership report for Chief Financial Officer Hagai Omri, disclosing an option to purchase 11,396 ordinary shares. The option has an exercise price of $7.6200 per share and expires on November 4, 2035.

As of the filing date, options to purchase 949 ordinary shares are vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to Omri’s continued service with the company.

Positive

  • None.

Negative

  • None.
Insider Hagai Omri
Role Chief Financial Officer
Type Security Shares Price Value
holding Option to Purchase Ordinary Shares -- -- --
Holdings After Transaction: Option to Purchase Ordinary Shares — 11,396 shares (Direct)
Footnotes (1)
  1. As of the date of this Form 3, options to purchase 949 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the NewcelX Ltd. Share Option Plan Regulation 2021 must be registered in the name of a trustee.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Hagai Omri

(Last)(First)(Middle)
C/O NEWCELX LTD.
THE CIRCLE 6

(Street)
ZURICH8058

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
NewcelX Ltd. [ NCEL ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Ordinary Shares (1)11/04/2035Ordinary Shares11,396(2)$7.62D
Explanation of Responses:
1. As of the date of this Form 3, options to purchase 949 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service.
2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the NewcelX Ltd. Share Option Plan Regulation 2021 must be registered in the name of a trustee.
/s/ Omri Hagai03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider holdings did NewcelX (NCEL) disclose for CFO Hagai Omri on Form 3?

NewcelX reported that CFO Hagai Omri holds an option to purchase 11,396 ordinary shares. This derivative position represents his initial disclosed equity-linked stake, setting a baseline for tracking any future exercises or changes in ownership.

How many NewcelX (NCEL) option shares are currently vested for CFO Hagai Omri?

As of the Form 3 filing date, options to purchase 949 NewcelX ordinary shares are vested and currently exercisable. This portion of the grant can be turned into shares at the stated exercise price if Omri chooses to exercise.

What is the exercise price and expiration date of Hagai Omri’s NewcelX (NCEL) options?

The disclosed option carries an exercise price of $7.6200 per ordinary share and expires on November 4, 2035. This long-dated structure links Omri’s potential upside to NewcelX’s share performance over an extended period.

How and when do Hagai Omri’s remaining NewcelX (NCEL) options vest?

The unvested portion of Omri’s 11,396-share option grant vests in 11 equal quarterly installments beginning May 4, 2026. Vesting is contingent on his continued service with NewcelX, aligning compensation with ongoing tenure.

What does NewcelX’s Form 3 filing indicate about Hagai Omri’s ownership type?

The filing classifies Hagai Omri’s option holding as direct ownership. This means the option to purchase 11,396 ordinary shares is attributed personally to him rather than through an intermediary entity or indirect structure.